The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S16-S17 , September 2007

Discussion Following Dr. Haffner’s Presentation

References 

  1. Hanley AJG, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes. 2004;53:2623–2632
  2. Hanley AJG, Williams K, Festa A, Wagenknecht LE, D’Agostino RB, Haffner SM. Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes. 2005;54:3140–3147
  3. Teixeira-Clerc F, Julien B, Grenard P, Tran Van Nhieu J, Deveaux V, Li L, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nature Medicine. 2006;12:671–676
  4. National Institute of Diabetes & Digestive & Kidney Diseases. Look Ahead: Action for Health in Diabetes Study. [NIDDK Website.]. Available at: http://www.niddk.nih.gov/patient/SHOW/lookahead.htm. Accessed July 24, 2006.
  5. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611–619

PII: S0002-9343(07)00546-3

doi: 10.1016/j.amjmed.2007.06.009

The American Journal of Medicine
Volume 120, Issue 9, Supplement 1 , Pages S16-S17 , September 2007

Article Tools